JW (Cayman) Therapeutics Co. Ltd. (2126) AI Stock Analysis

• Market Cap: HK$1.57B
• Dividend Yield: N/A
• Average Volume (3M): 2.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 2.45%
• EPS Growth: 2.58%
• Country: HK
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.70
• Shares Outstanding: 416,473,240
• 10 Day Avg. Volume: 1,852,649
• 30 Day Avg. Volume: 2,667,300
• PEG Ratio: 0.04
• Price to Book (P/B): 0.43
• Price to Sales (P/S): 3.14
• P/FCF Ratio: -1.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.04
• Price Target Upside: 75.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 39 Underperform
• Price Target: HK$3.50 ▲(1.45% Upside)

The company's financial performance is the most significant factor, with ongoing profitability challenges and negative cash flow impacting the score. Technical indicators suggest bearish momentum, and the valuation is unattractive due to negative earnings. The absence of earnings call insights and corporate events further limits the potential for a higher score.

JW (Cayman) Therapeutics Co. Ltd. Business Overview & Revenue Model

Company Description

JW (Cayman) Therapeutics Co. Ltd. (2126) is a biotechnology company focused on developing, manufacturing, and commercializing cell-based immunotherapies for cancer treatment. The company operates primarily in the healthcare and biotechnology sectors, with a core emphasis on chimeric antigen receptor T-cell (CAR-T) therapies. JW Therapeutics aims to innovate and provide transformative treatments for patients by leveraging cutting-edge biotechnological advancements and research in immunotherapy.

How the Company Makes Money

JW (Cayman) Therapeutics Co. Ltd. generates revenue primarily through the commercialization of its CAR-T cell therapy products. These products are designed to treat various types of cancer by harnessing the patient's immune system to target and destroy cancer cells. The company earns money through the sale of these therapies to healthcare providers and institutions. Additionally, JW Therapeutics may engage in strategic partnerships and collaborations with other biotechnology firms, research institutions, and pharmaceutical companies to enhance its research capabilities and expand its market reach. These partnerships can also provide financial support, shared resources, and access to broader distribution networks, contributing to the company's revenue. Furthermore, JW Therapeutics may receive funding and grants from government bodies or non-profit organizations to support its research and development efforts, although this is typically a smaller portion of its revenue stream compared to product sales.

JW (Cayman) Therapeutics Co. Ltd. Financial Statement Overview

Summary

Despite commendable revenue growth, the company faces significant profitability challenges with negative net income and EBIT margins. The balance sheet shows financial stability with a strong cash position, but negative operating cash flow and reliance on external funding highlight operational inefficiencies.

Income Statement

The company has shown consistent revenue growth over the years, with a notable increase from 2020 onwards. However, profitability remains a significant issue as the company has reported negative net income and EBIT margins throughout the years, indicating ongoing operational challenges. The gross profit margin has improved slightly, yet the high net losses overshadow these gains.

Balance Sheet

The company's balance sheet is relatively stable with a strong cash position, as indicated by the significant cash and cash equivalents. The debt-to-equity ratio remains low, suggesting conservative leverage. However, the continued net losses have adversely affected the return on equity, which remains negative. The equity ratio indicates a solid equity base compared to total assets, pointing to financial stability despite ongoing losses.

Cash Flow

Operating cash flow has been consistently negative, reflecting challenges in generating cash from operations. The company has managed to maintain a positive cash position largely through financing activities. Free cash flow remains negative, indicating that the company is not yet self-sustaining and relies on external funding to cover operational and capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	177.75M	158.22M	173.86M	145.70M	30.80M	0.00
Gross Profit	98.69M	77.32M	88.22M	58.76M	9.04M	0.00
EBITDA	-256.23M	-381.58M	-655.75M	-752.27M	-738.70M	-454.04M
Net Income	-617.62M	-590.62M	-768.00M	-846.13M	-702.33M	-1.66B
Balance Sheet
Total Assets	1.42B	1.68B	2.15B	2.79B	3.12B	3.78B
Cash, Cash Equivalents and Short-Term Investments	647.04M	762.53M	1.01B	1.39B	1.84B	2.63B
Total Debt	372.46M	422.40M	318.80M	279.13M	147.03M	123.59M
Total Liabilities	510.83M	511.20M	462.26M	437.06M	325.75M	349.76M
Stockholders Equity	908.61M	1.17B	1.68B	2.35B	2.79B	3.43B
Cash Flow
Free Cash Flow	-202.73M	-348.87M	-413.00M	-613.60M	-634.28M	-385.24M
Operating Cash Flow	-200.13M	-333.44M	-398.42M	-536.72M	-561.20M	-261.00M
Investing Cash Flow	-2.84M	-15.43M	9.90M	-124.08M	-137.13M	-91.91M
Financing Cash Flow	-20.67M	90.49M	275.00K	112.35M	-30.62M	2.86B

JW (Cayman) Therapeutics Co. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2126, the sentiment is Negative. The current price of 3.45 is below the 20-day moving average (MA) of 3.94, below the 50-day MA of 4.62, and above the 200-day MA of 2.94, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 35.54 is Neutral, neither overbought nor oversold. The STOCH value of 21.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2126.

JW (Cayman) Therapeutics Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9966	―	HK$11.53B	45.14	13.34%	―	206.58%	―
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2616	―	HK$9.18B	-20.28	-95.84%	―	-55.64%	-158.67%
2179	―	HK$3.35B	―	-129.05%	―	―	-18.99%
2157	―	HK$11.52B	-55.06	-21.42%	―	240.05%	-140.09%
2126	―	HK$1.57B	―	-51.56%	―	2.45%	2.58%

JW (Cayman) Therapeutics Co. Ltd. Corporate Events

JW Therapeutics Advances SLE Treatment with Promising Phase I Results

JW Therapeutics has submitted Phase I study data of Relmacabtagene autoleucel injection for treating active systemic lupus erythematosus (SLE) in Chinese adults to the National Medical Products Administration of China. The study demonstrated significant efficacy and a favorable safety profile for Relma-cel, with all 12 patients achieving SRI-4 remission and drug-free status, highlighting its potential as a new treatment option for SLE, a condition with significant unmet medical needs in China.

The most recent analyst rating on (HK:2126) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.

JW Therapeutics Advances with In-House Lentiviral Vector for Carteyva®

JW Therapeutics announced that the National Medical Products Administration of China has accepted its post-marketing supplementary application for Carteyva®, which now uses an in-house produced lentiviral vector. This development is significant as it ensures a stable supply and reduces costs, enhancing the commercial value of Carteyva® and strengthening JW Therapeutics’ position in the competitive cell therapy market.

The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.

JW Therapeutics Delays Circular Dispatch for Incentivization Scheme

JW (Cayman) Therapeutics Co. Ltd announced a delay in the dispatch of a circular related to the grant of options under its Post-IPO Incentivization Scheme. The company requires additional time to finalize the necessary information, now expecting to send the circular by December 31, 2025. This delay may impact shareholder expectations and timelines for the incentivization scheme.

The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.

JW Therapeutics Announces Share Options Grant to CEO

JW (Cayman) Therapeutics Co. Ltd. has announced the grant of 4,204,490 share options to Mr. Min Liu, the company’s chairman and CEO, under its Post-IPO Incentivization Scheme. This grant is subject to shareholder approval as it exceeds 1% of the company’s issued shares, highlighting the company’s commitment to aligning leadership incentives with shareholder interests.

The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.

JW Therapeutics Reports Revenue Growth Amid Operational Improvements

JW (Cayman) Therapeutics Co. Ltd. reported a 22.5% increase in revenue to RMB106.3 million for the first half of 2025, driven by sales of Carteyva® and licensing income. Despite a loss of RMB267.3 million due to an impairment charge, the company improved its operational efficiency, reducing selling, general, and R&D expenses, which led to a decrease in recurring operating loss by RMB126.5 million compared to the previous year.

The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.

JW Therapeutics to Review Interim Results in Upcoming Board Meeting

JW (Cayman) Therapeutics Co. Ltd. has announced a scheduled board meeting on August 27, 2025, to consider and approve the unaudited interim results for the first half of 2025. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and strategic direction for the upcoming months.